Meeting
2011 ASCO Annual Meeting
SYNERGY: A randomized phase III study comparing first-line docetaxel/prednisone to docetaxel/prednisone plus custirsen in metastatic castrate resistant prostate cancer (mCRPC).
Authors
K. N. Chi
British Columbia Cancer Agency, Vancouver, BC, Canada
K. N. Chi , J. S. De Bono , C. S. Higano
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session
Track
Special Sessions,Clinical Trials
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT01188187
Citation
J Clin Oncol 29: 2011 (suppl; abstr TPS180)
Abstract #
TPS180
Poster Bd #
46B
Abstract Disclosures
Similar Posters
Poster
2013 Genitourinary Cancers Symposium
A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed.
First Author: Susan Halabi
Poster
2012 Genitourinary Cancers Symposium
A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC‑1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy.
First Author: Maha Hussain
Poster
2023 ASCO Annual Meeting
A prospective trial of apalutamide and abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.
First Author: Daniel J. George
Poster
2016 Genitourinary Cancers Symposium
Use of crowdsourced research to develop a prognostic model for first-line metastatic castrate resistant prostate cancer (mCRPC).
First Author: Fang Liz Zhou